Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00226954 |
Recruitment Status :
Terminated
First Posted : September 27, 2005
Last Update Posted : March 18, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Primary:
To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently.
Secondary Objectives:
To describe the safety and tolerability at this dose and schedule
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Urologic Neoplasms | Drug: zoledronic acid | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 23 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer |
Study Start Date : | March 2003 |
Actual Primary Completion Date : | November 2007 |
Actual Study Completion Date : | February 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: Zoledronic Acid with Intermittent Hormonal Therapy |
Drug: zoledronic acid |
- To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently.
- To describe the safety and tolerability at this dose and schedule

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00226954
United States, California | |
Stanford University School of Medicine | |
Stanford, California, United States, 94305 |
Principal Investigator: | Dr. Sandy Srinivas | Stanford University |
Responsible Party: | Sandy Srinivas, PI, Stanford University |
ClinicalTrials.gov Identifier: | NCT00226954 |
Other Study ID Numbers: |
PROS0001 78869 PROS0001 |
First Posted: | September 27, 2005 Key Record Dates |
Last Update Posted: | March 18, 2020 |
Last Verified: | March 2020 |
Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms |
Zoledronic Acid Bone Density Conservation Agents Physiological Effects of Drugs |